Inhibrx Biosciences, Inc. (INBX)
NASDAQ: INBX · Real-Time Price · USD
80.36
+2.28 (2.92%)
At close: Dec 24, 2025, 1:00 PM EST
81.29
+0.93 (1.16%)
After-hours: Dec 24, 2025, 4:40 PM EST
Inhibrx Biosciences Revenue
In the year 2024, Inhibrx Biosciences had annual revenue of $200.00K, down -88.89%.
Revenue (ttm)
$200.00K
Revenue Growth
-88.89%
P/S Ratio
834.81
Revenue / Employee
$8,696
Employees
161
Market Cap
1.17B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 200.00K | -1.60M | -88.89% |
| Dec 31, 2023 | 1.80M | -392.00K | -17.88% |
| Dec 31, 2022 | 2.19M | -5.04M | -69.69% |
| Dec 31, 2021 | 7.23M | -5.66M | -43.89% |
| Dec 31, 2020 | 12.89M | -323.00K | -2.44% |
| Dec 31, 2019 | 13.21M | 4.62M | 53.71% |
| Dec 31, 2018 | 8.60M | 204.00K | 2.43% |
| Dec 31, 2017 | 8.39M | 1.72M | 25.86% |
| Dec 31, 2016 | 6.67M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
INBX News
- 1 day ago - Why Inhibrx's Recent Strength May Not Be Built to Last - Benzinga
- 9 days ago - Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program - PRNewsWire
- 5 weeks ago - Inhibrx Reports Third Quarter 2025 Financial Results - PRNewsWire
- 7 weeks ago - Inhibrx Announces Participation in Upcoming Scientific Conferences - PRNewsWire
- 2 months ago - Inhibrx: Positive Ozekibart Data For Bone Cancer Leads To Q2 2026 BLA Filing - Seeking Alpha
- 2 months ago - Inhibrx shares surge after bone cancer drug slows disease progression in trial - Reuters
- 2 months ago - Inhibrx Biosciences Reports Positive Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and Provides Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts - PRNewsWire
- 2 months ago - Inhibrx To Host Webcast Presentation of Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and to Provide Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts - PRNewsWire